Xilio’s New IND Tests Whether Masked IL-2 Can Make Immunotherapy Safer in Solid Tumors
The U.S. Food and Drug Administration has cleared Xilio Therapeutics to begin human testing of XTX501, a bispecific PD-1 and…
Category: Biotechnology
Third Time’s the Charm: FDA Finally Approves Replimune’s Melanoma Therapy
In a testament to clinical persistence, the U.S. Food and Drug Administration (FDA) has officially approved Replimune’s novel melanoma therapy,…
August FDA Action: Pluvicto Expands Reach as Moderna Awaits Landmark Flu Vaccine Decision
The first week of August 2026 is shaping up to be a defining period for the biotechnology and pharmaceutical sectors,…
FDA Advisory Panel Backs Replimune’s RP1 for Advanced Melanoma Ahead of August Decision
The biotechnology sector is closely watching the regulatory landscape this August, with several key Prescription Drug User Fee Act (PDUFA)…
Cell Therapy Is Entering a Harsher Evidence-Governance Era
One of the most revealing biotech developments of the last forty-eight hours was not a clinical breakthrough but a regulatory…
Biotech Manufacturing Is Becoming a Network Game
The most interesting biotech development of the last forty-eight hours is not a clinical readout or a regulatory designation. It…
AI Biotech Is Starting to Look Like a Real Business, Not Just a Thesis
Biotech investors have heard a decade of claims about how artificial intelligence would compress timelines, improve hit rates, and redesign…
TREGZI Turns the Transplant Itself Into the Therapy
Orca Bio’s newly approved TREGZI matters because it points to a different kind of innovation. Instead of treating transplant complications…
Biotech Buyers Are Paying for Cash-Flow Bridges, Not Just Science
The most revealing biotech deal of the past two days is not really a science-acquisition story at all. It is…
Biotech Corridors Are Becoming Products of Their Own
Biotech hubs used to sell themselves with a familiar formula: good universities, venture capital, hospital systems, and a deep pool…
Regulatory Speed Is Becoming Its Own Biotech Asset Class
The renewed fight over the FDA’s priority-voucher pathway suggests that review time is turning from an administrative variable into a…